1. Kaplan A, Heatley H, Townend J, Skinner D, Carter V, Hubbard R, Lee TT, Koh MS, Price D. The Real-World Impact of Glucagon-Like Peptide 1 Receptor Agonists on Asthma Control in People with High-Risk Asthma and Obesity. Adv Ther. 2025 Jun;42(6):2950-2956.

2. Sadatsafavi M, Tran TN, Scelo G, Tsai MJ, Busby J, Emmanuel B, Heaney LG, Jenkins C, Hoyte F, Canonica GW, Katial R, Heffler E, Wang E, Puggioni F, Wechsler ME, Ardusso LRF, Máspero J, Sivori M, Emmas C, Menzies-Gow AN, Stjepanovic N, Bosnic-Anticevich SZ, Cochrane B, Denton E, Gibson PG, Hew M, Middleton PG, Peters MJ, Brusselle GG, Louis R, Schleich F, Christoff GC, Popov TA, Bergeron C, Bhutani M, Chapman KR, Côté A, Couillard S, Dorscheid DR, Jiménez-Maldonado L, Solarte I, Torres-Duque CA, Hansen S, Porsbjerg CM, Ulrik CS, Altraja A, Bourdin A, Exarchos KP, Gogali A, Kostikas K, Makris MP, Papaioannou AI, Mitchell PD, Iwanaga T, Nagano T, Tohda Y, Al-Ahmad MS, Larenas-Linnemann D, Aarli BB, Kuna P, Chaves Loureiro C, Al-Lehebi R, Bulkhi AA, Chen W, Juang YR, Koh MS, Liu A, Rhee CK, Cosio BG, Perez-de-Llano L, Perng DW, Sheu CC, Wang HC, Mahboub B, Salameh L, Jackson DJ, Patel PH, Pfeffer PE, Lugogo N, Pleasants RA, Beastall A, Bulathsinhala L, Carter V, Eleangovan N, Fletton K, Townend J, Murray RB, Price DB. Prevention of Cardiovascular and Other Systemic Adverse Outcomes in Patients with Asthma Treated with Biologics. Am J Respir Crit Care Med. 2025 May 18. Epub ahead of print. 

3. Chen W, Tran TN, Townend J, Christoff GC, Tsai MJ, Altraja A, Cochrane B, Cosio BG, Sivori M, Murray RB, Makris MP, Scelo G, Bulathsinhala L, Ardusso LRF, Franchi ME, Máspero J, Saldarini F, Stok AM, Tomaszuk AG, Yañez A, Emmanuel B, Emmas C, Kostikas K, Menzies-Gow AN, Stjepanovic N, Bosnic-Anticevich SZ, Denton E, Gibson PG, Hew M, Jenkins C, Middleton PG, Peters MJ, Upham JW, Brusselle GG, Louis R, Schleich F, Pitrez PM, Popov TA, Bergeron C, Bhutani M, Chapman KR, Côté A, Couillard S, Dorscheid DR, Lougheed MD, Sadatsafavi M, Celis-Preciado CA, Jiménez-Maldonado L, Rodríguez-Cáceres B, Cano Rosales DJ, Solarte I, Torres-Duque CA, Hansen S, Porsbjerg CM, Ulrik CS, Bourdin A, Bakakos P, Exarchos KP, Gogali A, Ladias AA, Papadopoulos NG, Papaioannou AI, Costello RW, Cushen B, Mitchell PD, Canonica GW, Heffler E, Puggioni F, Iwanaga T, Nagano T, Tohda Y, Al-Ahmad MS, Larenas-Linnemann D, Aarli BB, Lehmann S, Kuna P, Ferreira JA, Fonseca JA, Loureiro CC, Al-Lehebi R, Bulkhi AA, Juang YR, Koh MS, Liu A, Rhee CK, Perez-de-Llano L, Fu PK, Perng DW, Sheu CC, Wang HC, Mahboub B, Salameh L, Busby J, Heaney LG, Jackson DJ, Patel PH, Pfeffer PE, Hoyte F, Katial RK, Lugogo N, Pleasants RA, Wang E, Wechsler ME, Beastall A, Carter V, Eleangovan N, Fletton K, Price DB; ISAR SOLAR I Working Group. Impact of Biologics Initiation on Oral Corticosteroid Use in the International Severe Asthma Registry and the Optimum Patient Care Research Database: A Pooled Analysis of Real-World Data. J Allergy Clin Immunol Pract. 2025 Apr 26:S2213-2198(25)00390-3. doi: 10.1016/j.jaip.2025.04.032. Epub ahead of print. 

4. Gonnelli F, Eleangovan N, Smith U, Heatley H, Navarantam V, Corte TJ, Price DB, Carter V, Bonifazi M, Fermoyle CC, Hubbard R. Incidence and survival of interstitial lung diseases in the UK in 2010-2019. ERJ Open Res. 2025 Mar 3;11(2):00823-2024.

5. Lynam A, Curtis C, Stanley B, Heatley H, Worthington C, Roberts EJ, Price C, Carter V, Dennis J, McGovern A, Price D. Data-Resource Profile: United Kingdom Optimum Patient Care Research Database. Pragmat Obs Res. 2023 Apr 27;14:39-49.

6. Loewenthal L, Busby J, McDowell R, Brown T, Burhan H, Chaudhuri R, Dennison P, Dodd JW, Doe S, Faruqi S, Gore R, Idris E, Jackson DJ, Patel M, Pantin T, Pavord I, Pfeffer PE, Price DB, Rupani H, Siddiqui S, Heaney LG, Menzies-Gow A; UK Severe Asthma Registry. Impact of sex on severe asthma: a cross-sectional retrospective analysis of UK primary and specialist care. Thorax. 2024 Apr 15;79(5):403-411.

7. Tran TN, Heatley H, Rowell J, Chan JSK, Bourdin A, Chapaneri J, Emmanuel B, Gibson D, Jackson DJ, Menzies-Gow AN, Murray R, Skinner D, Price DB. Longitudinal patterns of intermittent oral corticosteroid therapy for asthma in the United Kingdom. J Allergy Clin Immunol Glob. 2024 Feb 2;3(2):100225.

8. Horne EMF, McLean S, Alsallakh MA, Davies GA, Price DB, Sheikh A, Tsanas A. Defining clinical subtypes of adult asthma using electronic health records: Analysis of a large UK primary care database with external validation. Int J Med Inform. 2023 Feb;170:104942.

9. Ryan D, Heatley H, Heaney LG, Jackson DJ, Pfeffer PE, Busby J, Menzies-Gow AN, Jones R, Tran TN, Al-Ahmad M, Backer V, Belhassen M, Bosnic-Anticevich S, Bourdin A, Bulathsinhala L, Carter V, Chaudhry I, Eleangovan N, FitzGerald JM, Gibson PG, Hosseini N, Kaplan A, Murray RB, Rhee CK, Van Ganse E, Price DB. Potential Severe Asthma Hidden in UK Primary Care. J Allergy Clin Immunol Pract. 2021 Apr;9(4):1612-1623.e9. doi: 10.1016/j.jaip.2020.11.053. Epub 2020 Dec 9. Erratum in: J Allergy Clin Immunol Pract. 2021 Nov;9(11):4182.

10. Magnussen H, Lucas S, Lapperre T, Quint JK, Dandurand RJ, Roche N, Papi A, Price D, Miravitlles M; Respiratory Effectiveness Group (REG). Withdrawal of inhaled corticosteroids versus continuation of triple therapy in patients with COPD in real life: observational comparative effectiveness study. Respir Res. 2021 Jan 21;22(1):25.

1. Nilsbakken IMW, Wisborg T, Sollid S, Jeppesen E. EMCC dispatch priority for trauma patients in Norway: a retrospective cohort study. Scand J Trauma Resusc Emerg Med. 2025 May 12;33(1):83.

2. Ringdal KG, Holm KT, Røise O. The Norwegian national trauma registry: development process and essential data insights. Scand J Trauma Resusc Emerg Med. 2025 May 1;33(1):78.

3. Aalberg I, Nordseth T, Klepstad P, Rosseland LA, Uleberg O. Incidence, severity and changes of abnormal vital signs in trauma patients: A national population-based analysis. Injury. 2025 Jan;56(1):111884.

4. Bjørke G, Dalen I, Thorsen K. Accuracy of the Norwegian trauma protocol. An observational population study from South-Western Norway. Injury. 2025 Jan;56(1):112063.

5. Sødal HF, Nordseth T, Rasmussen AJO, Rosseland LA, Stenehjem JS, Gran JM, Helseth E, Taubøll E. Risk of epilepsy after traumatic brain injury: a nationwide Norwegian matched cohort study. Front Neurol. 2024 Jun 5;15:1411692.

6. Nilsbakken I, Wisborg T, Sollid S, Jeppesen E. Functional outcome and associations with prehospital time and urban-remote disparities in trauma: A Norwegian national population-based study. Injury. 2024 Jun;55(6):111459.

7. Naberezhneva N, Uleberg O, Dahlhaug M, Giil-Jensen V, Ringdal KG, Røise O. Excellent agreement of Norwegian trauma registry data compared to corresponding data in electronic patient records. Scand J Trauma Resusc Emerg Med. 2023 Sep 26;31(1):50.

8. Dehli T, Wisborg T, Johnsen LG, Brattebø G, Eken T. Mortality after hospital admission for trauma in Norway: A retrospective observational national cohort study. Injury. 2023 Sep;54(9):110852.

9. Cuevas-Østrem M, Thorsen K, Wisborg T, Røise O, Helseth E, Jeppesen E. Care pathways and factors associated with interhospital transfer to neurotrauma centers for patients with isolated moderate-to-severe traumatic brain injury: a population-based study from the Norwegian trauma registry. Scand J Trauma Resusc Emerg Med. 2023 Jun 26;31(1):34.

10. Nilsbakken IMW, Sollid S, Wisborg T, Jeppesen E. Assessing Trauma Management in Urban and Rural Populations in Norway: A National Register-Based Research Protocol. JMIR Res Protoc. 2022 Jun 17;11(6):e30656.

1. Palsson O, Love TJ, Wallman JK, Kapetanovic MC, Gunnarsson PS, Gudbjornsson B. Prescription of non-steroidal anti-inflammatory drugs for patients with inflammatory arthritis decreases with the initiation of tumour necrosis factor inhibitor therapy: results from the ICEBIO registry. Scand J Rheumatol. 2024 Nov;53(6):402-408.

2. Ørnbjerg LM, Brahe CH, Linde L, Jacobsson L, Nissen MJ, Kristianslund EK, Santos MJ, Nordström D, Rotar Z, Gudbjornsson B, Onen F, Codreanu C, Lindström U, Möller B, Kvien TK, Barcelos A, Eklund KK, Tomšič M, Love TJ, Can G, Ionescu R, Loft AG, Mann H, Pavelka K, van de Sande M, van der Horst-Bruinsma IE, Suarez MP, Sánchez-Piedra C, Macfarlane GJ, Iannone F, Michelsen B, Hyldstrup LH, Krogh NS, Østergaard M, Hetland ML. Drug effectiveness of 2nd and 3rd TNF inhibitors in psoriatic arthritis - relationship with the reason for withdrawal from the previous treatment. Joint Bone Spine. 2024 Jul;91(4):105729.

3. Linde L, Ørnbjerg LM, Heegaard Brahe C, Wallman JK, Di Giuseppe D, Závada J, Castrejon I, Díaz-Gonzalez F, Rotar Z, Tomšič M, Glintborg B, Gudbjornsson B, Geirsson AJ, Michelsen B, Kristianslund EK, Santos MJ, Barcelos A, Nordström D, Eklund KK, Ciurea A, Nissen M, Akar S, Hejl Hyldstrup L, Krogh NS, Hetland ML, Østergaard M. Second and third TNF inhibitors in European patients with axial spondyloarthritis: effectiveness and impact of the reason for switching. Rheumatology (Oxford). 2024 Jul 1;63(7):1882-1892.

4. Ørnbjerg LM, Rugbjerg K, Georgiadis S, Rasmussen SH, Jacobsson L, Loft AG, Iannone F, Fagerli KM, Vencovsky J, Santos MJ, Möller B, Pombo-Suarez M, Rotar Z, Gudbjornsson B, Cefle A, Eklund K, Codreanu C, Jones G, van der Sande M, Wallman JK, Sebastiani M, Michelsen B, Závada J, Nissen MJ, Sanchez-Piedra C, Tomšič M, Love TJ, Relas H, Mogosan C, Hetland ML, Østergaard M. Patient-reported outcomes and PRO remission rates in 12,262 biologic-naïve patients with psoriatic arthritis treated with TNF-inhibitors in routine care. J Rheumatol. 2024 Jan 15:jrheum.2023-0764.

5. Glintborg B, Di Giuseppe D, Wallman JK, Nordström DC, Gudbjornsson B, Hetland ML, Askling J, Grondal G, Sokka T, Provan SA, Michelsen B, Kristianslund EK, Dreyer L, Love TJ, Lindström U. Uptake and effectiveness of newer biologic and targeted synthetic disease-modifying antirheumatic drugs in psoriatic arthritis: results from five Nordic biologics registries. Ann Rheum Dis. 2023 Jun;82(6):820-828.

6. Nissen M, Delcoigne B, Di Giuseppe D, Jacobsson L, Hetland ML, Ciurea A, Nekvindova L, Iannone F, Akkoc N, Sokka-Isler T, Fagerli KM, Santos MJ, Codreanu C, Pombo-Suarez M, Rotar Z, Gudbjornsson B, van der Horst-Bruinsma I, Loft AG, Möller B, Mann H, Conti F, Yildirim Cetin G, Relas H, Michelsen B, Avila Ribeiro P, Ionescu R, Sanchez-Piedra C, Tomsic M, Geirsson ÁJ, Askling J, Glintborg B, Lindström U. The impact of a csDMARD in combination with a TNF inhibitor on drug retention and clinical remission in axial spondyloarthritis. Rheumatology (Oxford). 2022 Nov 28;61(12):4741-4751.

7. Delcoigne B, Provan SA, Hammer HB, Di Giuseppe D, Frisell T, Glintborg B, Grondal G, Gudbjornsson B, Hetland ML, Michelsen B, Nordström D, Relas H, Askling J. Do patient-reported measures of disease activity in rheumatoid arthritis vary between countries? Results from a Nordic collaboration. Rheumatology (Oxford). 2022 Nov 2;61(11):4286-4296.

8. Di Giuseppe D, Lindström U, Aaltonen K, Relas H, Provan S, Gudbjornsson B, Hetland ML, Askling J, Kauppi M, Geirsson AJ, Chatzidionysiou K, Jørgensen TS, Dreyer L, Michelsen B, Jacobsson L, Glintborg B. The occurrence of multiple treatment switches in axial spondyloarthritis. Results from five Nordic rheumatology registries. Rheumatology (Oxford). 2022 Aug 30;61(9):3647-3656.

9. Michelsen B, Georgiadis S, Di Giuseppe D, Loft AG, Nissen MJ, Iannone F, Pombo-Suarez M, Mann H, Rotar Z, Eklund KK, Kvien TK, Santos MJ, Gudbjornsson B, Codreanu C, Yilmaz S, Wallman JK, Brahe CH, Möller B, Favalli EG, Sánchez-Piedra C, Nekvindova L, Tomsic M, Trokovic N, Kristianslund EK, Santos H, Löve TJ, Ionescu R, Pehlivan Y, Jones GT, van der Horst-Bruinsma I, Ørnbjerg LM, Østergaard M, Hetland ML. Real-World Six- and Twelve-Month Drug Retention, Remission, and Response Rates of Secukinumab in 2,017 Patients With Psoriatic Arthritis in Thirteen European Countries. Arthritis Care Res (Hoboken). 2022 Jul;74(7):1205-1218.

10. Glintborg B, Lindström U, Giuseppe DD, Provan SA, Gudbjornsson B, Hetland ML, Michelsen B, Wallman JK, Aaltonen K, Hokkanen AM, Nordström D, Jørgensen TS, Hansen RL, Geirsson AJ, Grøn KL, Krogh NS, Askling J, Kristensen LE, Jacobsson LTH; Danish Rheumatology Database (DANBIO), Anti-Rheumatic Therapy in Sweden/Swedish Rheumatology Quality (ARTIS/SRQ), Center for Rheumatology Research (ICEBIO), Finnish Register of Biological Treatment (ROB-FIN), and Norwegian Antirheumatic Drug Register (NOR-DMARD) registries. One-Year Treatment Outcomes of Secukinumab Versus Tumor Necrosis Factor Inhibitors in Spondyloarthritis: Results From Five Nordic Biologic Registries Including More Than 10,000 Treatment Courses. Arthritis Care Res (Hoboken). 2022 May;74(5):748-758.